Protea Biopharma
Belgian biotechnology company focused on R&D of improved diagnostics and therapeutics for infectious and chronic immune diseases. Core activities include biomarker discovery (notably RNase L pathway), drug discovery for antiviral and immunomodulatory compounds, development of urine-based point-of-care diagnostic assays for immune balance monitoring, and maintenance of an active patent portfolio. Assays developed by the company are commercialized via a clinical laboratory distributor on a fee-for-service basis.
Industries
Nr. of Employees
small (1-50)
Protea Biopharma
Products
Urine-based Th1/Th2 balance test kit (research use only)
A single-analysis urine kit intended to detect alterations in systemic Th1/Th2 balance to allow repeated self-monitoring and follow-up during therapy; distributed as research-use-only pending CE marking.
Urine-based Th1/Th2 balance test kit (research use only)
A single-analysis urine kit intended to detect alterations in systemic Th1/Th2 balance to allow repeated self-monitoring and follow-up during therapy; distributed as research-use-only pending CE marking.
Services
Commercialization and performance of developed diagnostic assays through a clinical laboratory distributor on a fee-for-service basis.
Commercialization and performance of developed diagnostic assays through a clinical laboratory distributor on a fee-for-service basis.
Expertise Areas
- Biomarker discovery
- Antiviral drug discovery
- Immunology (innate immunity and intracellular antiviral pathways)
- Diagnostic assay development
Key Technologies
- Urine-based point-of-care assays
- Molecular assays of RNase L / 2-5A pathway
- Real-time PCR for viral DNA quantification
- Biochemical enzyme activity assays (e.g., elastase, PKR assays)
News & Updates
Study describing dysregulation in the 2-5A/RNase L pathway in peripheral blood mononuclear cells of chronic fatigue syndrome patients and the protective role of higher 2-5A oligomers against RNase L cleavage.
Study on PKR activation and its role in cellular response to stress and oxidative cytotoxicity.
Review article summarizing evidence for intracellular immune dysfunction in ME/CFS and discussing potential therapeutic targets in the 2-5A synthetase/RNase L pathway.
Study using real-time PCR to quantify viral DNA loads in gastrointestinal biopsies, identifying parvovirus B19 and other viruses in a subset of patients.
Reported holding and pursuit of multiple patents in the US and Europe (stated total of 13 patents granted or under examination; two patents awarded and three applications filed in the prior 12 months as described on the site).
Study describing dysregulation in the 2-5A/RNase L pathway in peripheral blood mononuclear cells of chronic fatigue syndrome patients and the protective role of higher 2-5A oligomers against RNase L cleavage.
Study on PKR activation and its role in cellular response to stress and oxidative cytotoxicity.
Review article summarizing evidence for intracellular immune dysfunction in ME/CFS and discussing potential therapeutic targets in the 2-5A synthetase/RNase L pathway.
Study using real-time PCR to quantify viral DNA loads in gastrointestinal biopsies, identifying parvovirus B19 and other viruses in a subset of patients.
Reported holding and pursuit of multiple patents in the US and Europe (stated total of 13 patents granted or under examination; two patents awarded and three applications filed in the prior 12 months as described on the site).